- Report
- June 2025
- 185 Pages
Global
From €4004EUR$4,500USD£3,477GBP
- Report
- August 2025
- 150 Pages
Global
From €5295EUR$5,950USD£4,598GBP
- Report
- May 2025
- 100 Pages
Global
From €5295EUR$5,950USD£4,598GBP
- Report
- January 2026
- 184 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- January 2026
- 197 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- January 2026
- 183 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- January 2026
- 182 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- January 2026
- 196 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- January 2026
- 185 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- August 2025
- 184 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- August 2025
- 180 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- August 2025
- 192 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- August 2025
- 188 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- August 2025
- 191 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- August 2025
- 180 Pages
Global
From €3505EUR$3,939USD£3,044GBP
- Report
- January 2026
- 488 Pages
Global
From €5206EUR$5,850USD£4,520GBP
- Report
- January 2026
- 287 Pages
Global
From €5206EUR$5,850USD£4,520GBP
- Report
- January 2026
- 291 Pages
Global
From €5206EUR$5,850USD£4,520GBP
- Report
- January 2026
- 271 Pages
Global
From €5206EUR$5,850USD£4,520GBP
- Report
- January 2026
- 276 Pages
Global
From €5206EUR$5,850USD£4,520GBP

Adalimumab is a biologic drug used to treat a variety of immune disorders, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, and juvenile idiopathic arthritis. It is a monoclonal antibody that works by blocking the action of tumor necrosis factor (TNF), a protein that plays a role in inflammation. Adalimumab is administered by subcutaneous injection and is available in both brand-name and generic forms.
Adalimumab is one of the most widely prescribed drugs for immune disorders, and it has been approved for use in more than 100 countries. It is a highly effective treatment for many of the conditions it is used to treat, and it has been shown to improve quality of life for patients.
Some of the companies in the Adalimumab market include AbbVie, Amgen, Biogen, Boehringer Ingelheim, Janssen Biotech, Merck, and Pfizer. Show Less Read more